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Pharmaceuticals in Drinking Water:  In the News...
© Cummins, 2012
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How do pharmaceutical products used by humans enter the 
environment?
Primary entry points:
Manufacturing, Disposal, or Contamination:
Regulated by the EPA, REACH  
Patient Use:
Regulated by the FDA, EMA, FASS
Discharged to the environment through wastewater 
treatment systems.  
© Boxall et al, 2012
© Yang et al, 2017
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How can pharmaceutical products move through the environment?
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Why are pharmaceuticals in the environment a concern?
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Why are pharmaceuticals in the environment a concern?
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United States
National Environmental Policy Act (NEPA)
Federal agencies must assess the environmental 
impacts of their actions.
FDA: Environmental Assessments (EAs):
• New and Investigational Drug Applications;
• Abbreviated and Supplemented Applications;
❖ unless the action qualifies for categorical 
exclusion.
An EA adequate for approval must enable the 
Agency to determine whether the proposed action 
may affect significantly the quality of the human 
environment.
Natural Substances: 
Categorically Excluded  
when approval will not
significantly alter the 
concentration or distribution 
of the substance, its 
metabolites, or degradation 
products in the environment.
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FDA Guidance
EIC: Expected Introduction Concentration
EICAQUATIC = A * B * C * D 
Where: 
A= kg/yr produced for direct use (as active moiety) 
B = 1/ 1.214 x 1011 liters per day entering POTWs 
C = year/365 days 
D = 109 g/kg (conversion factor) 
 
 
Categorical Exclusion: 
• EIC of the Active Ingredient < 1 ppb, and
• No extenuating circumstances (EAT, 
bioaccumulation).
US Department of Health and Human Services, Food and Drug Administration. 
Guidance for Industry.  Environmental Assessment of Human Drug and 
Biologics Applications. July 1998, CMC 6; Revision 1.
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European Union
European Medicines Agency (EMA): 
A decentralised agency of the 
European Union (EU) responsible for 
the scientific evaluation, supervision 
and safety monitoring of medicines in 
the EU (EMA 2019).
Environmental Risk Assessment (ERA)
• Marketing Authorization for a 
medicinal product for human use;
❖ can be a justification for not 
completing additional environmental 
studies.
European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).  Guideline 
on the Environmental Risk Assessment of Medicinal Products for Human Use 
(EMEA/CHMP/SWP/4447/00).  01 Jun 2006.
Natural Substances:
• ERA required for products 
containing natural 
substances (e.g. vitamins, 
electrolytes, amino acids, 
etc, vaccines, and herbal 
products);
• limited to statement that 
environmental studies are 
not required.
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EMA Guidance
PEC= Predicted Environmental Concentration
European Medicines Agency (EMA) Committee for Medicinal Products for Human Use 
(CHMP).  Guideline on the Environmental Risk Assessment of Medicinal Products for 
Human Use (EMEA/CHMP/SWP/4447/00).  01 Jun 2006.
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EMA GUIDANCE
The assessment of potential risks is a step-wise procedure:
PECSURFACEWATER is < 0.01 g/L AND no other concerns (e.g. PBT) 
STOP at Phase I.
European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).  Guideline on the 
Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00).  01 Jun 2006.
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Environmental Strategy
EMA- Phase I required; Evaluate PEC and Kow to determine need for Phase II studies 
FDA- Evaluate EIC, EAT, Log Kow characteristics to determine CE or EA
EMA > 0.01 g/L
FDA > 1 g/L
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EXAMPLE
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EU EMA: Tiered Studies
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EU EMA: Tiered Studies
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EXAMPLE
  
 
Phase I 
Log Kow 
5.14 Via 
Slow-Stir 
Is Log Kow 
>4.5? 
 
No Yes 
Screen for PBT 
OECD 305 Study 
Completed 
STOP 
Calculation of PEC 
PEC = 0.375 g/L 
Is PEC < 0.01 µg/L? 
NO 
Dose  
75 mg/ 
inh*d 
No Yes 
Proceed to 
Phase II, Tier A 
 
Adsorption/ 
Desorption  
OECD 106  
 Fish Dietary 
Accumulation Study 
OECD 305-III 
Daphnia Life Cycle 
Toxicity 
OECD 211                                    
1 
Activated Sludge 
Respiration Inhib. 
OECD 209  
Sediment: Aerobic 
Transformation 
OECD 308 
Algae Acute 
Toxicity 
OECD 201  
Fathead Minnow 
Toxicity  
OECD 210  
Mean Koc = 
14,987 L/kg 
BMF = 0.067 
Growth Corr. BMF = 0.058 
Lipid Corr. BMF = 0.021 
Growth & Lipid Corr. BMF = 0.023 
 
37.8%-71.6% 
Sediment Bound 
at Day 101  
EC15 (NOEC) was 
> 2,0000 mg/L  
NOEC =   
0.085 mg/L 
NOEC =  
0.52 mg/L 
NOEC =  
0.057 mg/L 
 
Was mean Koc > 
10,000 L/kg 
YES Phase II, Tier B 
Terrestrial Studies 
Required 
Soil Microflora 
OECD 216 
Seedling Emergence 
OECD 208 
Collembola Toxicity 
OECD 232 
Had more than 10% of 
the API partitioned to 
sediment after 14 days?  
YES 
Phase II, Tier B 
Midge Study Required 
API had no inhibitory effect on the respiration 
rate of microorganisms in sludge. 
 
NOEC =  
5,678 mg/k 
All BMF < 0.1 
No Bioaccumulation 
STOP 
No PBT 
STOP 
No Risk 
PEC/PNECSED 
=0.042/56.78 
=0.00074 < Action Limit of 1 
Earthworm Toxicity 
OECD 207 
NOEC =  
150 mg/kg 
NOEC >  
80 mg/kg 
EC50 >  
2,000 mg/kg 
NOEC =  
100 mg/kg 
Aerobic Degradation 
OECD 307 
API rapidly & 
extensively 
degraded 
 
While the results of the environmental studies did not indicate any 
risks to the environment, we still recommend the inclusion of the 
following in the product’s package information sheet. 
“Medicines should not be disposed of via wastewater or household 
waste.  Ask your pharmacist how to dispose of medicines no longer 
required.  These measures will help to protect the environment." 
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CANADA
Canadian Environmental Protection Act, 1999:
If the compound is not on the Domestic Substances List , it can not be 
manufactured or imported in excess of the maximum quantity allowed by the 
guidelines.
Canada has introduced draft 
regulations that are more similar 
to those of the EU.
Environment Canada. Guidelines for the notification and 
testing of new substances - chemicals and polymers.  
2006.
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SWEDEN
Environmental information on the Active 
Pharmaceutical Ingredients (API) is provided 
at www.fass.se. 
Environmental information:
• Focuses on aquatic systems,
• Provided by pharmaceutical companies,
• Reviewed by the Swedish Environmental 
Research Institute (IVL). 
FASS.SE reports contain:
• Summary phrases about the 
environmental risk, degradation and 
bioaccumulation; and
• Detailed background information.
Läkemedelsindustriföreningens Service AB(LIF).  
Environmental classification of pharmaceuticals at 
www.fass.se.  Guidance for pharmaceutical 
companies.  2012 
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SWEDEN
Läkemedelsindustriföreningens Service AB(LIF).  Environmental classification of 
pharmaceuticals at www.fass.se.  Guidance for pharmaceutical companies.  2012 
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SWEDEN
Läkemedelsindustriföreningens Service AB(LIF).  Environmental classification of 
pharmaceuticals at www.fass.se.  Guidance for pharmaceutical companies.  2012 
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PHARMACEUTICALS IN THE ENVIRONMENT (PIE)-AbbVie
AbbVie is committed to monitoring our operations to ensure that the 
manufacture, use and disposal of our products do not adversely affect human 
health or the environment. We support continuing research to further 
understand issues surrounding pharmaceuticals in the environment, which 
can guide what we do in the future. 
To achieve this, we: 
• Provide regulatory authorities with environmental risk assessments that are 
used to evaluate potential environmental risks associated with patient use 
of our medications. 
• Continually evaluate the potential for environmental risks of our active 
pharmaceutical ingredients. 
• Partner with industry organizations such as the Pharmaceutical Research 
and Manufacturers of America (PhRMA) and the European Federation of 
Pharmaceutical Industries and Associations (EFPIA) in order to improve 
methods to identify and quantify environmental risks. 
https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/our-
environmental-stewardship.pdf
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Disclosures
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contributed to the design; participated in the collection, 
analysis, and interpretation of data, and in writing, 
reviewing, and approval of the final presentation. 

